These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16585196)

  • 21. Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse.
    Kim M; Yan Y; Lee K; Sgagias M; Cowan KH
    Biochem Biophys Res Commun; 2004 Jul; 320(3):945-50. PubMed ID: 15240140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X; Wang J; Messing EM; Wu G
    Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility.
    Hsu T; Adereth Y; Kose N; Dammai V
    J Biol Chem; 2006 Apr; 281(17):12069-80. PubMed ID: 16505488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VHL gene mutation and clear-cell renal carcinomas.
    Knudson AG
    Cancer J Sci Am; 1995; 1(3):180-1. PubMed ID: 9166471
    [No Abstract]   [Full Text] [Related]  

  • 25. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
    Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
    J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
    Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
    Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J; Rettig MB
    Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
    Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
    Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
    Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
    Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer].
    Mikhaĭlenko DS; Grigor'eva MV; Rusakov IG; Kurynin RV; Popov AM; Peters MV; Matveev VB; Iakovlev ES; Nosov DA; Liubchenko LN; Tiuliandin SA; Strel'nikov VV; Zaletaev DV
    Mol Biol (Mosk); 2012; 46(1):71-81. PubMed ID: 22642103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.
    Bouhamdani N; Joy A; Barnett D; Cormier K; Léger D; Chute IC; Lamarre S; Ouellette R; Turcotte S
    Int J Cancer; 2017 Aug; 141(4):778-790. PubMed ID: 28486780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
    Peruzzi B; Athauda G; Bottaro DP
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.